Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 11/20 | 1.00 |
| ▸ | RAB9A | P51151 | 7/20 | 1.00 |
| ▸ | NPC1 | O15118 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | ATM | Q13315 | 1/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | CCR1 | P32246 | 2/20 | 0.59 |
| ▸ | CCR5 | P51681 | 2/20 | 0.59 |
| ▸ | CCR8 | P51685 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | METAP1 | P53582 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.59 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.57 |
| ▸ | TP53 | P04637 | 6/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15671504 | 0.87 | KDM4E (0.77) | KDM4ERAB9ANPC1MAPTATM | |
| SCHEMBL29870798 | 0.87 | KDM4E (0.77) | KDM4ERAB9ANPC1MAPTATM | |
| SCHEMBL11982530 | 0.86 | KDM4E (0.74) | KDM4ERAB9ANPC1MAPTATM | |
| SCHEMBL1107860 | 0.86 | KDM4E (0.74) | KDM4ERAB9ANPC1MAPTATM | |
| SCHEMBL17135790 | 0.86 | KDM4E (0.74) | KDM4ERAB9ANPC1MAPTATM | |
| SCHEMBL8143194 | 0.86 | KDM4E (0.74) | KDM4ERAB9ANPC1MAPTATM | |
| SCHEMBL1098775 | 0.86 | KDM4E (0.74) | KDM4ERAB9ANPC1MAPTATM | |
| SCHEMBL971007 | 0.86 | KDM4E (0.74) | KDM4ERAB9ANPC1MAPTATM | |
| SCHEMBL1208215 | 0.84 | KDM4E (0.70) | KDM4ERAB9ANPC1MAPTATM | |
| SCHEMBL22761302 | 0.82 | KDM4E (0.69) | KDM4ERAB9ANPC1MAPTATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120535765-A | Three-dimensional cobalt-based MOF material, preparation method thereof and application thereof in conversion of carbon dioxide into oxazolidinone derivatives | 太原师范学院 | 2025-08-26 | — | — | CN | disclosed |
| US-20250186411-A1 | Methods of Treating Disorders Associated with Overactivation of IKKB | US GOV VETERANS AFFAIRS (US) | 2025-06-12 | — | — | US | disclosed |
| US-8598208-B2 | Pyridine derivatives as S1P1/EDG1 receptor modulators | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-12-03 | — | — | US | disclosed |
| US-20110212998-A1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
| EP-2195311-B1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-03-23 | — | — | EP | disclosed |
| EP-2195311-A1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | Actelion Pharmaceuticals Ltd. (CH) | 2010-06-16 | — | — | EP | disclosed |
| WO-2009024905-A1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-02-26 | — | — | WO | disclosed |
| US-4853396-A | 2,5-BIS(PYRIDYL)-1,3,4-THIADIAZOLES | CIBA-GEIGY CORPORATION (US) | 1989-08-01 | — | — | US | disclosed |
| US-4853396-A | 2,5-BIS(PYRIDYL)-1,3,4-THIADIAZOLES | CIBA-GEIGY CORPORATION (US) | 1989-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186411-A1 | Methods of Treating Disorders Associated with Overactivation of IKKB | NFKBIA, IKBKG, IKBKB | KDM4E 2712/4885RAB9A 3272/4885NPC1 1123/4885 |
| US-20110212998-A1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | S1PR1, S1PR3, S1PR2 | KDM4E 919/4885RAB9A 2456/4885NPC1 1256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.